JP2018501189A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501189A5
JP2018501189A5 JP2017504036A JP2017504036A JP2018501189A5 JP 2018501189 A5 JP2018501189 A5 JP 2018501189A5 JP 2017504036 A JP2017504036 A JP 2017504036A JP 2017504036 A JP2017504036 A JP 2017504036A JP 2018501189 A5 JP2018501189 A5 JP 2018501189A5
Authority
JP
Japan
Prior art keywords
sample
somatic stem
composition
donor
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504036A
Other languages
Japanese (ja)
Other versions
JP2018501189A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061257 external-priority patent/WO2016081553A1/en
Publication of JP2018501189A publication Critical patent/JP2018501189A/en
Publication of JP2018501189A5 publication Critical patent/JP2018501189A5/ja
Pending legal-status Critical Current

Links

Claims (14)

２μｍ〜８．０μｍの大きさであり、Ｌｇｒ５＋又はＣＤ３４９＋である体性幹細胞を含む、骨欠損を治療するための組成物であって、骨欠損部位に投与されることを特徴とする、組成物。 A composition for treating a bone defect comprising somatic stem cells having a size of 2 μm to 8.0 μm and being Lgr5 + or CD349 +, wherein the composition is administered to a bone defect site Thing . 前記体性幹細胞がＣＤ１３３−、ＣＤ３４−、ＣＤ９０−、ＣＤ６６ｅ−、ＣＤ３１−、Ｌｉｎ１−、ＣＤ６１−、Ｏｃｔ４＋、Ｎａｎｏｇ＋及びＳｏｘ２−である、請求項１に記載の組成物。 The composition according to claim 1, wherein the somatic stem cells are CD133-, CD34-, CD90-, CD66e-, CD31-, Lin1-, CD61-, Oct4 +, Nanog + and Sox2-. 前記体性幹細胞がＬｇｒ５＋である、請求項１又は２に記載の組成物。 The composition according to claim 1 or 2, wherein the somatic stem cells are Lgr5 +. 前記体性幹細胞は以下の手法：
ドナー由来のサンプルが上層及び下層に分離するまで、容器内で該サンプルをＥＤＴＡ又はヘパリンとともにインキュベーションすること、
該上層を回収すること、及び
２μｍ〜８．０μｍの大きさの、Ｌｇｒ５＋又はＣＤ３４９＋である体性幹細胞集団を該上層から単離すること、
により得られる、請求項１又は２に記載の組成物。 The somatic stem cells can be obtained by the following method:
Incubating the sample with EDTA or heparin in a container until the donor-derived sample separates into upper and lower layers,
Recovering the upper layer, and isolating a somatic stem cell population that is Lgr5 + or CD349 + in a size of 2 μm to 8.0 μm from the upper layer,
The composition of Claim 1 or 2 obtained by these . 前記サンプルが血液又は骨髄サンプルである、請求項４に記載の組成物。 The composition of claim 4, wherein the sample is a blood or bone marrow sample. 前記ドナーから前記サンプルを得る前に、前記ドナーに顆粒球コロニー刺激因子又はフコイダンが投与されている、請求項５に記載の組成物。 6. The composition of claim 5, wherein granulocyte colony stimulating factor or fucoidan is administered to the donor prior to obtaining the sample from the donor. 前記体性幹細胞が対象に対して自己又は異種のものである、請求項１又は２に記載の組成物。 The composition according to claim 1 or 2, wherein the somatic stem cells are autologous or heterologous to a subject. ドナー由来のサンプルが上層及び下層に分離するまで、容器内で該サンプルをＥＤＴＡ又はヘパリンとともにインキュベーションすること、
該上層を回収すること、及び
約２μｍ〜８．０μｍの大きさの、Ｌｇｒ５＋又はＣＤ３４９＋である体性幹細胞集団を該上層から単離すること
を含む、約２μｍ〜８．０μｍの大きさの、Ｌｇｒ５＋又はＣＤ３４９＋である体性幹細胞を製造する方法。 Until samples from donors is separated into the upper and lower layers, incubating the sample with EDTA or heparin in the vessel,
Recovering the upper layer and isolating somatic stem cell populations of Lgr5 + or CD349 + in a size of about 2 μm to 8.0 μm from the upper layer
The including approximately the size of 2μm~8.0μm of a method for producing a somatic stem cell is a LGR5 + or CD349 +. 前記サンプルが血液又は骨髄サンプルである、請求項８に記載の方法。   9. The method of claim 8, wherein the sample is a blood or bone marrow sample. 前記上層からＬｉｎ＋細胞及びＣＤ６１＋細胞を取り除くことを更に含む、請求項９に記載の方法。   10. The method of claim 9, further comprising removing Lin + cells and CD61 + cells from the upper layer. 前記ドナーから前記サンプルを得る前に、前記ドナーに顆粒球コロニー刺激因子又はフコイダンが投与されている、請求項９又は１０に記載の方法。 The method according to claim 9 or 10, wherein granulocyte colony-stimulating factor or fucoidan is administered to the donor before obtaining the sample from the donor. 前記ドナーが骨欠損の対象又は別の対象である、請求項１１に記載の方法。   12. The method of claim 11, wherein the donor is a bone defect subject or another subject. 骨移植片又は骨移植片代替物と組み合わせて投与されることを更なる特徴とする、請求項１〜７のいずれか一項に記載の組成物。 The composition according to any one of claims 1 to 7 , further characterized in that it is administered in combination with a bone graft or bone graft substitute. 前記体性幹細胞が足場に移植される、請求項１〜７及び１３のいずれかに記載の組成物。 The composition according to any one of claims 1 to 7 and 13, wherein the somatic stem cells are transplanted to a scaffold.
JP2017504036A 2014-11-19 2015-11-18 Somatic stem cells for treating bone defects Pending JP2018501189A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081880P 2014-11-19 2014-11-19
US62/081,880 2014-11-19
PCT/US2015/061257 WO2016081553A1 (en) 2014-11-19 2015-11-18 Somatic stem cells for treating bone defects

Publications (2)

Publication Number Publication Date
JP2018501189A JP2018501189A (en) 2018-01-18
JP2018501189A5 true JP2018501189A5 (en) 2018-11-29

Family

ID=55960744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504036A Pending JP2018501189A (en) 2014-11-19 2015-11-18 Somatic stem cells for treating bone defects

Country Status (7)

Country Link
US (3) US20160136203A1 (en)
EP (1) EP3220929A4 (en)
JP (1) JP2018501189A (en)
CN (2) CN113521107A (en)
HK (1) HK1232131A1 (en)
TW (2) TW202224691A (en)
WO (1) WO2016081553A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075433A1 (en) * 2016-10-18 2018-04-26 StemBios Technologies, Inc. Composition and method for decreasing bilirubin level

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2936171B2 (en) * 1989-09-01 1999-08-23 東ソー株式会社 Method for producing serum albumin
WO1999026639A1 (en) * 1997-11-26 1999-06-03 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
US6175420B1 (en) * 1998-05-20 2001-01-16 Zymequest, Inc. Optical sensors for cell processing systems
JP3553858B2 (en) * 1999-08-25 2004-08-11 東洋紡績株式会社 Cell culture module having a vascular network-like structure
US7011761B2 (en) * 1999-09-03 2006-03-14 Baxter International Inc. Red blood cell processing systems and methods which control red blood cell hematocrit
US20020020680A1 (en) * 2000-06-20 2002-02-21 Glen Jorgensen Blood component preparation (BCP) device and method of use thereof
US6610002B2 (en) * 2001-04-09 2003-08-26 Medtronic, Inc. Method for handling blood sample to ensure blood components are isolated
US6790371B2 (en) * 2001-04-09 2004-09-14 Medtronic, Inc. System and method for automated separation of blood components
US6890291B2 (en) * 2001-06-25 2005-05-10 Mission Medical, Inc. Integrated automatic blood collection and processing unit
US7806845B2 (en) * 2002-04-24 2010-10-05 Biomet Biologics, Llc Blood separation and concentration system
JP2004123716A (en) * 2002-08-06 2004-04-22 Mitsubishi Pharma Corp Medicine for preventing and/or treating hepatic disorder caused by chemical substance
JP2004099560A (en) * 2002-09-11 2004-04-02 Hiroshi Makino Medicine for prevention and/or treatment of drug-induced nephropathy
ES2265199B1 (en) * 2003-06-12 2008-02-01 Cellerix, S.L. MOTHER CELLS MULTIPOTENT ADULTS FROM DEDIFFERENTIATED DRIVERS AND ITS APPLICATIONS.
ES2364878T3 (en) * 2004-09-03 2011-09-15 Moraga Biotechnology Inc. NON-EMBRYONARY TOTIPOTENTIAL BLASTOMER-TYPE STEM CELLS AND THE SAME PROCEDURES.
US20090104695A1 (en) * 2004-12-29 2009-04-23 Etti Ben Shushan Stem Cells Culture Systems
JP4722508B2 (en) * 2005-02-23 2011-07-13 日本メナード化粧品株式会社 Identification and isolation culture method of pluripotent stem cells
SG177946A1 (en) * 2005-08-29 2012-02-28 Technion Res & Dev Foundation Media for culturing stem cells
CA2640087A1 (en) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
EP1991666A4 (en) * 2006-02-27 2009-06-10 Moraga Biotech Corp Non-embryonic totipotent blastomere-like stem cells and methods therefor
EP2489728A1 (en) * 2006-06-15 2012-08-22 Neostem, Inc Processing procedure for peripheral blood stem cells
EP2420567A3 (en) * 2006-10-23 2015-09-30 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
KR20090109127A (en) * 2007-02-12 2009-10-19 안트로제네시스 코포레이션 Hepatocytes and chondrocytes from adherent placental stem cells? and cd34?, cd45? placental stem cell-enriched cell populations
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
CA2693144A1 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP2022848A1 (en) * 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
CN101978046A (en) * 2007-10-30 2011-02-16 路易斯维尔大学研究基金会有限公司 Uses and isolation of very small embryonic-like (vsel) stem cells
US8455251B2 (en) * 2007-11-09 2013-06-04 Rnl Bio Co., Ltd. Method for isolating and culturing adult stem cells derived from human amniotic epithelium
GB2467982A (en) * 2008-05-08 2010-08-25 Coretherapix Slu Pluripotent adult stem cells
WO2010039241A1 (en) * 2008-09-30 2010-04-08 University Of Louisville Research Foundation, Inc. Methods for isolating very small embryonic-like (vsel) stem cells
US20110305673A1 (en) * 2008-11-12 2011-12-15 The University Of Vermont And State Agriculture College Compositions and methods for tissue repair
CN101748096B (en) * 2008-12-17 2013-03-13 北京汉氏联合生物技术有限公司 Sub totipotential stem cell and preparation method and application thereof
WO2010083203A2 (en) * 2009-01-13 2010-07-22 StemBios Technologies, Inc. Non-embryonic stem cells and uses thereof
CN102421467B (en) * 2009-03-13 2015-04-22 梅约医学教育与研究基金会 Bioartificial liver
US20140219952A1 (en) * 2010-03-23 2014-08-07 The Johns Hopkins University Methods of treatment using stem cell mobilizers
CA2835313A1 (en) * 2010-05-07 2011-11-10 Institut De Recherches Cliniques De Montreal Gfi1b modulation and uses thereof
SG10201913920PA (en) * 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
TWI596211B (en) * 2010-08-04 2017-08-21 幹細胞生物科技公司 Somatic stem cells
CN102008650B (en) * 2010-12-16 2017-02-15 天津市医药科学研究所 Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof
BR112013025957A2 (en) * 2011-04-08 2016-09-20 Neostem Inc methods and compositions for bone and cartilage regeneration by autograft of very small embryonic pluripotent stem cells from adult humans (hvsels)
MY171285A (en) * 2011-08-05 2019-10-07 Stemtech Int Inc Skin care compositions containing combinations of natural ingredients
TWI571513B (en) * 2011-09-28 2017-02-21 幹細胞生物科技股份有限公司 Somatic stem cells and method of preparing same
EP2929013B1 (en) * 2012-12-06 2020-02-05 Stembios Technologies, Inc. Lgr5+ somatic stem cells
TWI640884B (en) * 2013-06-24 2018-11-11 幹細胞生物科技公司 Method of obtaining stem cells and their data
CN105687245A (en) * 2014-12-13 2016-06-22 干细胞生物科技公司 Method of preparing injection solution

Similar Documents

Publication Publication Date Title
JP2015521054A5 (en)
HRP20201487T1 (en) Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
RU2015148585A (en) IMPROVEMENT OF BODIES FOR TRANSPLANTATION
WO2008108412A1 (en) Serum preparation method and serum preparation apparatus
ECSP19073391A (en) CLARIFICATION OF CELL CROPS
CL2021000208A1 (en) Method for producing cells derived from dental pulp
CN103469309A (en) Method for separating living cell and constructing cell bank by means of tissue homogenate method
Hilpert et al. p19INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging
Harris et al. Preparing e18 cortical rat neurons for compartmentalization in a microfluidic device
EA201790662A2 (en) COMPOSITIONS AND METHODS FOR EXTRACTING AND / OR REMOVING REAGENTS FROM A POROUS ENVIRONMENT
JP2018501189A5 (en)
JP2016510766A5 (en)
GB2574333A (en) Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma
CN104316526A (en) Method for observing morphological structure in mesophyll of fossil plant
US20210093676A1 (en) Somatic stem cells for treating bone defects
Solis-Correa et al. Apical papilla stem cells and polyurethane based scaffolds, a new approach for the development of constructs in tissue engineering
Parham et al. Growth Rate of Equine Marrow-Derived Versus Fat-derived Mesenchymal Stem Cells
Amirpour Review of Effect of Storage Time before Freezing on Stem Cells Surveillance, Collected from Cord Blood, Peripheral Blood and Bone Marrow
RU2022121959A (en) ORGAN IMPROVEMENT FOR TRANSPLANTATION
Kazemi et al. Investigating Survival and Differentiation of Mesenchymal Stem Cells to Vascular Cells and Components when Seeded on a Decellularized Aortic Scaffold
Uccelli et al. Mesenchymal Stem Cells Shape Microglia Effector Functions through The Release of CX-3CL1.
UA107240U (en) METHOD OF OBTAINING PERG
Abedin et al. Preparation of a declassified 3D bone matrix from human epiphyseal bone
Quispe Siccha et al. Controlled dehydration of polyvinyl alcohol as a method for seeding and preservation of alive cells
Serrano et al. The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-b-2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation